Efektivitas Penggunaan Remdesivir terhadap Outcome Pasien COVID-19 di RSUD Embung Fatimah Kota Batam
DOI:
https://doi.org/10.23917/saintek.v1i1.552Keywords:
COVID-19 , Remdesivir , Usia, Dosis, OutcomeAbstract
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by a new type of coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). This study was conducted to determine the effectiveness of the use of Remdesivir on the outcomes of COVID-19 patients at Embung Fatimah Hospital, Batam City. Remdesivir is the first drug to be approved by the US Food and Drug Administration (USFDA) as an Emergency Use Authorization (EUA) for hospital treatment administered to COVID-19 patients. This type of research is descriptive analytic with retrospective data collection. The analysis uses the Chi-square test to see the relationship between variables. The results obtained based on the gender of male patients by 53%, based on the age of 46-55 years by 32%, and based on the length of treatment the most days were found to be less than 14 days by 65%. The number of uses of Remdesivir in each COVID-19 patient is different, the highest result in the number of uses is less than equal to 6 injections by 81%, with the dose given is 200 mg on the first day, followed by 100 mg on day 2- 5. The results of the Chi-square test with a p-value of 0.029 show that the use of Remdesivir on the outcome of COVID-19 patients can be used.
Downloads
References
Awdisma, W. M., Nosa, U. S., Hasmono, D., & Nurmainah, N. (2021). Kajian Literatur: Tinjauan Remdesivir sebagai Pilihan Terapi pada COVID-19. Jurnal Pharmascience, 8(2), 121. https://doi.org/10.20527/jps.v8i2.11650
Badan Pengawasan Obat dan Makanan Republik Indonesia. (2020). Informatorium Obat Covid.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., et al. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764
BPOM. (2021). Informatorium Obat Covid-19 di Indonesia Edisi 3. BPOM RI.
Burhan, E., Susanto, A. D., Nasution, S. A., Ginanjar, E., Pitoyo, W., Susilo, A., et al. Pedoman Tatalaksana COVID-19 Edisi 3.
Cai, H. (2020). Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine, 8(4), e20. https://doi.org/10.1016/S2213-2600(20)30117-X
Darmalaksana, W. (2021). Semangat Sembuh dari Paparan Covid dengan Bas. Journal of Chemical Information and Modeling, 4(1), 6.
Elviani, R., Anwar, C., & Sitorus, R. J. (2021). Gambaran Usia Pada Kejadian Covid-19. Jambi Medical Journal, 9(2), 204–209.
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., et al. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/10.1056/NEJMoa2007016
Han, Y., & Yang, H. (2020). The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. Journal of Medical Virology, 92(6), 639–644. https://doi.org/10.1002/jmv.25749
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Istyanto, F., & Maghfiroh, A. (2021). Peran Mikronutrisi Sebagai Upaya Pencegahan Covid-19. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, 11(April), 5–6.
Keputusan Menteri Kesehatan Republik Indonesia. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19), 207.
Levani., Prastya., & Mawaddatunnadila. (2021). Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. Jurnal Kedokteran dan Kesehatan, 17(1), 44–57.
Lilyawati, S. A., Fitriani, N., & Prasetya, F. (2019). Studi Literatur: Penggunaan Obat Remdesivir dan Favipiravir dalam terapi Covid-19. Proceeding of Mulawarman Pharmaceuticals Conferences, 135–138. Retrieved from http://prosiding.farmasi.unmul.ac.id/index.php/mpc/article/view/416/399
Luetkemeyer, A., Kline, S., Castilla, D. L. De., Finberg, R. W., Dierberg, K., Tapson, V., et al. (2020). New England Journal, 1813–1826. https://doi.org/10.1056/NEJMoa2007764
Masturoh, I., & Anggata, N. (2018). Metodologi Penelitian Kesehatan.
Nawangsari, H. (2021). Hubungan Karakteristik Individu Dengan Pengetahuan Tentang Pencegahan Coronavirus Disease 2019 Pada Masyarakat Di Kecamatan Pungging Mojokerto. Sentani Nursing Journal, 4(1), 46–51. https://doi.org/10.52646/snj.v4i1.97
Perhimpunan Dokter Paru Indonesia. (2020). Panduan Praktik Klinis: Pneumonia COVID-19. Journal of the American Pharmacists Association, 55(5), 1–67.
SATGAS. (2021). Data COVID-19 Kepulauan Riau.
U.S. Food & Drug Administration. (2020). Veklury (remdesivir) EUA Letter of Approval, reissued 10/22/2020, 1–7.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0
WHO. (2021). WHO Coronavirus (COVID-19) Dashboard.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Suhaera, Messy Oktavia Hamzah, Henny Rachdiati
This work is licensed under a Creative Commons Attribution 4.0 International License.
